JP2008538769A - ジペプチドを含むパーソナルケア組成物 - Google Patents
ジペプチドを含むパーソナルケア組成物 Download PDFInfo
- Publication number
- JP2008538769A JP2008538769A JP2008508009A JP2008508009A JP2008538769A JP 2008538769 A JP2008538769 A JP 2008538769A JP 2008508009 A JP2008508009 A JP 2008508009A JP 2008508009 A JP2008508009 A JP 2008508009A JP 2008538769 A JP2008538769 A JP 2008538769A
- Authority
- JP
- Japan
- Prior art keywords
- thr
- dipeptide
- alk
- lys
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 146
- 108010016626 Dipeptides Proteins 0.000 title claims abstract description 79
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims abstract description 7
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000004473 Threonine Substances 0.000 claims abstract description 5
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims abstract 2
- 239000002537 cosmetic Substances 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 14
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 210000004899 c-terminal region Anatomy 0.000 claims description 9
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 8
- ZOKVLMBYDSIDKG-CSMHCCOUSA-N Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ZOKVLMBYDSIDKG-CSMHCCOUSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims description 4
- XNSKSTRGQIPTSE-ACZMJKKPSA-N Arg-Thr Chemical compound C[C@@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O XNSKSTRGQIPTSE-ACZMJKKPSA-N 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- WRPDZHJNLYNFFT-GEVIPFJHSA-N His-Thr Chemical group C[C@@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N)O WRPDZHJNLYNFFT-GEVIPFJHSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 17
- 238000011269 treatment regimen Methods 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 87
- 210000001519 tissue Anatomy 0.000 description 54
- 210000004209 hair Anatomy 0.000 description 52
- 210000000282 nail Anatomy 0.000 description 48
- 239000012071 phase Substances 0.000 description 26
- 108090000765 processed proteins & peptides Proteins 0.000 description 26
- 239000000839 emulsion Substances 0.000 description 23
- 230000000699 topical effect Effects 0.000 description 23
- 239000000047 product Substances 0.000 description 22
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 20
- 239000004615 ingredient Substances 0.000 description 20
- 239000003921 oil Substances 0.000 description 17
- 230000032683 aging Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 230000006378 damage Effects 0.000 description 12
- 239000000049 pigment Substances 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 239000004408 titanium dioxide Substances 0.000 description 10
- 230000037303 wrinkles Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- -1 serums Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 229940088594 vitamin Drugs 0.000 description 9
- 229930003231 vitamin Natural products 0.000 description 9
- 235000013343 vitamin Nutrition 0.000 description 9
- 239000011782 vitamin Substances 0.000 description 9
- FGSPQNZCLMWQAS-GPXNEJASSA-N (2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FGSPQNZCLMWQAS-GPXNEJASSA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 239000010445 mica Substances 0.000 description 8
- 229910052618 mica group Inorganic materials 0.000 description 8
- 229920001296 polysiloxane Polymers 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 239000002562 thickening agent Substances 0.000 description 7
- RTBWWWVNZWFNBV-SFHVURJKSA-N (2s)-3-phenyl-2-(undec-10-enoylamino)propanoic acid Chemical compound C=CCCCCCCCCC(=O)N[C@H](C(=O)O)CC1=CC=CC=C1 RTBWWWVNZWFNBV-SFHVURJKSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 239000003086 colorant Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitrogen oxide Inorganic materials O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 229920002379 silicone rubber Polymers 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000007613 environmental effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- QZLXCFQVOCEKSX-NOCHOARKSA-N (2s,4r)-1-hexadecanoyl-4-hexadecanoyloxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H]1C[C@@H](C(O)=O)N(C(=O)CCCCCCCCCCCCCCC)C1 QZLXCFQVOCEKSX-NOCHOARKSA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 208000001840 Dandruff Diseases 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000003212 astringent agent Substances 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 210000004709 eyebrow Anatomy 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000008092 positive effect Effects 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000007665 sagging Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 239000000516 sunscreening agent Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 2
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 2
- 241000239290 Araneae Species 0.000 description 2
- 208000035484 Cellulite Diseases 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
- 206010049752 Peau d'orange Diseases 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 206010043189 Telangiectasia Diseases 0.000 description 2
- 206010044625 Trichorrhexis Diseases 0.000 description 2
- 241000212749 Zesius chrysomallus Species 0.000 description 2
- 239000003082 abrasive agent Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 229940067599 ascorbyl glucoside Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000003139 biocide Substances 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 229940036350 bisabolol Drugs 0.000 description 2
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000008294 cold cream Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000007854 depigmenting agent Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 210000004905 finger nail Anatomy 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 210000004919 hair shaft Anatomy 0.000 description 2
- VAMFXQBUQXONLZ-UHFFFAOYSA-N icos-1-ene Chemical compound CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 210000000088 lip Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 208000026721 nail disease Diseases 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 229940101267 panthenol Drugs 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 235000020957 pantothenol Nutrition 0.000 description 2
- 239000011619 pantothenol Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 210000004003 subcutaneous fat Anatomy 0.000 description 2
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 2
- 229910052815 sulfur oxide Inorganic materials 0.000 description 2
- 230000008833 sun damage Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000009056 telangiectasis Diseases 0.000 description 2
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 2
- 229910001887 tin oxide Inorganic materials 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 210000004906 toe nail Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 229960001325 triclocarban Drugs 0.000 description 2
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- GXKYGCGTJAIHDJ-UHFFFAOYSA-N 1-iodoheptan-4-yl carbamate Chemical compound CCCC(OC(N)=O)CCCI GXKYGCGTJAIHDJ-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 241001237961 Amanita rubescens Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 206010015967 Eye swelling Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 206010019030 Hair colour changes Diseases 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- NRCMAYZCPIVABH-UHFFFAOYSA-N Quinacridone Chemical compound N1C2=CC=CC=C2C(=O)C2=C1C=C1C(=O)C3=CC=CC=C3NC1=C2 NRCMAYZCPIVABH-UHFFFAOYSA-N 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- XSEPSRUDSPHMPX-KATARQTJSA-N Thr-Lys-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O XSEPSRUDSPHMPX-KATARQTJSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000002682 anti-psoriatic effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- SVURIXNDRWRAFU-OGMFBOKVSA-N cedrol Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1[C@@](O)(C)CC2 SVURIXNDRWRAFU-OGMFBOKVSA-N 0.000 description 1
- 229940026455 cedrol Drugs 0.000 description 1
- PCROEXHGMUJCDB-UHFFFAOYSA-N cedrol Natural products CC1CCC2C(C)(C)C3CC(C)(O)CC12C3 PCROEXHGMUJCDB-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000003745 detangling effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 description 1
- 235000019126 equol Nutrition 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 230000003741 hair volume Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
- 229960001915 hexamidine Drugs 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 210000000003 hoof Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- SVURIXNDRWRAFU-UHFFFAOYSA-N juniperanol Natural products C1C23C(C)CCC3C(C)(C)C1C(O)(C)CC2 SVURIXNDRWRAFU-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 239000007934 lip balm Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- CBKLICUQYUTWQL-XWGBWKJCSA-N methyl (3s,4r)-3-methyl-1-(2-phenylethyl)-4-(n-propanoylanilino)piperidine-4-carboxylate;oxalic acid Chemical compound OC(=O)C(O)=O.CCC(=O)N([C@]1([C@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 CBKLICUQYUTWQL-XWGBWKJCSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 125000000627 niacin group Chemical class 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- CGIHFIDULQUVJG-UHFFFAOYSA-N phytantriol Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)(O)C(O)CO CGIHFIDULQUVJG-UHFFFAOYSA-N 0.000 description 1
- CGIHFIDULQUVJG-VNTMZGSJSA-N phytantriol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(O)[C@H](O)CO CGIHFIDULQUVJG-VNTMZGSJSA-N 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 229940081510 piroctone olamine Drugs 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000036558 skin tension Effects 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- AAAQKTZKLRYKHR-UHFFFAOYSA-N triphenylmethane Chemical compound C1=CC=CC=C1C(C=1C=CC=CC=1)C1=CC=CC=C1 AAAQKTZKLRYKHR-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cosmetics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本発明の組成物は以下に詳細に記載される。
一つの態様において、本発明のパーソナルケア組成物は、
(1)ジペプチド;
(2)皮膚科学的に又は経口に許容可能な担体、あるいは注射可能な液体;及び
(3)所望により、任意構成要素
を含む。
別の態様では、本方法は、ジペプチドを注射する、好ましくはジペプチドを皮膚中及び/又は皮膚下に注射する工程を含む。特定の実施形態では、本方法は、本発明のジペプチドの注射及び/又は経口投与及び/又は局所適用の組み合わせを含む処置レジメンを含む。
本発明の組成物は、ジペプチド活性物質を含む。本明細書で使用するとき、用語「ジペプチド」は、1以上のジペプチド類、1以上のジペプチド類の誘導体、及びこれらの組み合わせを含むのに十分に広義である。好ましくは、組成物は、有効な量の、好ましくは安全且つ有効な量のこのようなジペプチドを含む。
Bは、−NH2、−NH3 +、−NH−Dであり、
Dは、炭素原子2〜22個の長さのアシル基、又はビオチニルであり、
Eは、−O−Alk、−NR1R2、−H、−O-、又は−OHであり、
式中、Alkは、炭素1〜24個の長さのアルキル基であり、R1及びR2は、独立してH又は炭素1〜12個の長さのアルキル基である。特に好ましい実施形態では、Bは−NH−Dである。分子のA(それぞれLys、Arg、及びHis)は、pH6.0で個々の荷電状態にあることが示されることに留意すること。それらは、非荷電状態で存在してもよく、上記の表示Aは、両方を包含することを意味することが理解される。
これは、例えば皺の著しい減少、向上した効能、皮膚、毛髪、又は爪における少なくとも1つの生化学的プロセスを著しい程度に促進又は阻害する能力等であり得る。一般に、これは、対照との比較に基づき決定される。
本発明の組成物は、1以上の好適な所望の任意構成要素を含むことができる。例えば、組成物は、所望により他の活性又は不活性成分を含むことができる。ナイアシンアミドのような任意のケラチン組織活性物質と組み合わせてペプチドを含む組成物は、相加的及び/又は相乗的なケラチン組織(例えば、皮膚、毛髪、又は爪)の効果を提供することが可能であり得る。
本発明の組成物は、所望の製品形態によって、経口に又は皮膚科学的に許容可能な担体、又は注射可能な液体を含むことができる。
また、本発明の局所適用組成物は、組成物に、皮膚科学的に許容可能な担体も含むことができる。一実施形態では、担体は、組成物の約50重量%〜約99.99重量%、好ましくは約60重量%〜約99.9重量%、より好ましくは約70重量%〜約98重量%、さらにより好ましくは約80重量%〜約95重量%の濃度で存在する。
また本発明の組成物は、それが摂取されるとき、経口に許容可能な担体も含むことができる。当該技術分野において、ないしは別の方法で既知である、あらゆる好適な経口に摂取可能な担体又は担体形態を使用することができる。経口パーソナルケア組成物の非限定例としては、錠剤、ピル、カプセル、ドリンク、飲料、パウダー、ビタミン、サプリメント、ヘルスバー、キャンディ、ガム、及びドロップを挙げることができるが、これらに限定されない。
また本発明の組成物は、組成物が注射される場合、皮膚内及び/又は皮膚下への注射に許容可能な液体を含むことができる。当該技術分野においてないしは別の方法で既知である、あらゆる好適な許容可能な液体を使用することができる。
一般に、本発明の方法において有用な組成物は、局所用及び経口用組成物、並びに注射のための組成物を作製する、当該技術分野において既知である方法のような、従来の方法により調製される。このような方法は、典型的に、加熱、冷却、真空の適用等を用いて又は用いずに、成分を1つ以上の工程で混合して比較的均一な状態にすることを含むことができる。
本発明の組成物は、多数の哺乳類のケラチン組織の状態を処置するのに有用であり得る。このようなケラチン組織状態の処置は、哺乳類のケラチン組織の美容的外見を調節することを包含する、予防的及び治療的調節を含むことができる。より具体的には、そのような処置方法は、不均一な皮膚の色調を防止、遅延、及び/又は処置すること、哺乳類の皮膚の毛穴の大きさを縮めること、哺乳類の皮膚の脂っぽい/てかてかした外見を調整すること、ケラチン組織を厚くすること(即ち、皮膚の表皮及び/又は真皮及び/又は皮下層の構築、適用可能であれば爪及び毛幹のケラチン層の構築)、美白又は色素沈着を減少させる化粧品として作用することによって皮膚の色調が不均一になるのを防止、遅延、及び/又は処置すること、哺乳類の皮膚の萎縮を防止、遅延、及び/又は処置すること、哺乳類の口唇、毛髪及び爪を軟化させる及び/又は滑らかにすること、哺乳類の皮膚の痒みを防止、遅延、及び/又は処置すること、目の下のクマ及び/又は腫れぼったい目の外見を防止、遅延、及び/又は処置すること、哺乳類の皮膚の血色の悪さを防止、遅延、及び/又は処置すること、哺乳類の皮膚のたるみ(即ち、グリケーション)を防止、遅延、及び/又は処置すること、哺乳類の皮膚の日焼けを防止及び/又は遅延すること、哺乳類の皮膚を落屑させ、剥離させ、及び/又は代謝回転を向上させること、炎症後の過度の色素沈着等の過度の色素沈着を防止、遅延、及び/又は処置すること、哺乳類の皮膚上にクモ状血管及び/又は赤色斑点が現れるのを防止、遅延、及び/又は処置すること、哺乳類の皮膚の小皺及び皺を防止、遅延、及び/又は処置すること、皮膚の乾燥(即ち、荒れ、鱗屑、粉状の剥がれ)を防止、遅延、及び/又は処置すること、並びに哺乳類の皮膚にセルライトの出現を防止、遅延、及び/又は処置することを対象とすることができるが、これらに限定されない。好ましい実施形態では、本組成物は、老化の兆候を処置するために使用される。一つの態様において、本組成物は、老化の兆候を調節するために使用される。別の態様では、本組成物は、老化の兆候を低減又は低下するために使用される。さらに別の態様では、本組成物は、ケラチン組織(例えば、皮膚、毛髪、又は爪)における老化の兆候を防止するために使用される。
さらに、ケラチン組織状態の調節は、安全且つ有効な量の本発明の組成物を経口摂取することを含むことができる。摂取される組成物の量、摂取頻度、及び使用期間は、所与の組成物の構成要素の濃度、並びに、例えば存在する又は発生が予想されるケラチン組織の損傷の程度を考慮した、所望の調整の程度に応じて、広範囲に渡って異なるであろう。
2パルミトイル−リジン−トレオニン、セダーマ(Sederma)より入手可能
3二酸化チタン被覆雲母紫色干渉顔料、エッカート(Eckart)より入手可能
4シリカ及び二酸化チタン被覆雲母赤色干渉顔料、ロナ(Rona)より入手可能
2パルミトイル−リジン−トレオニン、セダーマ(Sederma)より入手可能
3シリコーンエラストマー分散体、ダウ・コーニング社(Dow Corning Corp)より
4シリコーンエラストマー分散体、信越(Shin Etsu)より
5二酸化チタン及び酸化スズ被覆雲母緑色干渉顔料、エンゲルハード(Engelhard)より
6二酸化チタン被覆雲母赤色干渉顔料、エッカート(Eckart)より
2KSG−21、信越(Shin Etsu)より入手可能な乳化型シリコーンエラストマー
3シリコーンエラストマー分散体、ダウ・コーニング社(Dow Corning Corp)より
4エイビル(Abil)EM−97、ゴールドシュミット・ケミカル・コーポレーション(Goldschmidt Chemical Corporation)より入手可能
2パルミトイル−リジン−トレオニン、セダーマ(Sederma)より入手可能
3二酸化チタン被覆雲母紫色干渉顔料、エッカート(Eckart)より入手可能
4シリカ及び二酸化チタン被覆雲母赤色干渉顔料、ロナ(Rona)より入手可能
2パルミトイル−リジン−トレオニン、セダーマ(Sederma)より入手可能
3シリコーンエラストマー分散体、ダウ・コーニング社(Dow Corning Corp)より
4シリコーンエラストマー分散体、信越(Shin Etsu)より
5二酸化チタン及び酸化スズ被覆雲母緑色干渉顔料、エンゲルハード(Engelhard)より
6二酸化チタン被覆雲母赤色干渉顔料、エッカート(Eckart)より
Claims (10)
- (a)ジペプチド系分子、ここで、前記ジペプチド系分子のC末端アミノ酸はトレオニンである;及び
(b)皮膚科学的に又は経口に許容可能な担体、あるいは注射可能な液体
を含むパーソナルケア組成物。 - 前記ジペプチド系分子のN末端アミノ酸が、塩基性アミノ酸であり、好ましくは前記ジペプチド系分子のN末端アミノ酸が、リジン、アルギニン、及びヒスチジンから成る群から選択され、より好ましくは前記ジペプチド系分子のN末端アミノ酸が、リジンである請求項1に記載のパーソナルケア組成物。
- 前記アミノ酸が、前記ジペプチド系分子のNアシル誘導体を含み、好ましくは前記Nアシル誘導体がエステルである請求項1又は2に記載のパーソナルケア組成物。
- 前記C末端アミノ酸が窒素含有誘導体である請求項1から3のいずれか1項に記載のパーソナルケア組成物。
- 前記ジペプチドが、His−Thr、Arg−Thr、Lys−Thr、Alk−His−Thr、Alk−Arg−Thr、Alk−Lys−Thr、His−Thr−OAlk、Arg−Thr−OAlk、Lys−Thr−OAlk、His−Thr−NR1R2、Arg−Thr−NR1R2、Lys−Thr−NR1R2、Alk−His−Thr−OAlk、Alk−Lys−Thr−NR1R2、Alk−Lys−Thr−OAlk、及びこれらの組み合わせから成る群から選択される誘導体である請求項1に記載のパーソナルケア組成物。
- Bが−NH−D又はHであり、AがNH3 +(CH2)4−である請求項6に記載の組成物。
- Eが−O-又は−OHである請求項6または7に記載の組成物。
- (a)ジペプチド系分子、ここで、前記ジペプチド系分子は、His−Thr、Arg−Thr、Lys−Thr、Alk−His−Thr、Alk−Arg−Thr、Alk−Lys−Thr、His−Thr−OAlk、Arg−Thr−OAlk、Lys−Thr−OAlk、His−Thr−NR1R2、Arg−Thr−NR1R2、Lys−Thr−NR1R2、Alk−His−Thr−OAlk、Alk−Lys−Thr−NR1R2、又はAlk−Lys−Thr−OAlkを含み、ここで、Alkは、N−アシル誘導体を指し、OAlkは、前記ThrのC末端カルボニルに付着するアルキル基であり、R1及びR2は、独立して、H又は炭素原子1〜12個の長さのアルキル基である;並びに
(b)皮膚科学的に又は経口に許容可能な担体、あるいは注射可能な液体
を含むパーソナルケア組成物。 - 前記組成物が、皮膚科学的に許容可能な担体を含み、前記組成物が、哺乳類ケラチン組織の美容的外見を調節するのに有効な量の前記ジペプチドを含み、好ましくは前記組成物が、前記組成物の約0.000001重量%〜約10重量%の濃度の前記ジペプチドを含む請求項1から9のいずれか1項に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67526405P | 2005-04-27 | 2005-04-27 | |
US60/675,264 | 2005-04-27 | ||
PCT/US2006/016418 WO2006116731A2 (en) | 2005-04-27 | 2006-04-27 | Personal care compositions comprising a dipeptide |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008538769A true JP2008538769A (ja) | 2008-11-06 |
JP4990268B2 JP4990268B2 (ja) | 2012-08-01 |
Family
ID=36968807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008508009A Active JP4990268B2 (ja) | 2005-04-27 | 2006-04-27 | ジペプチドを含むパーソナルケア組成物 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20070020220A1 (ja) |
EP (1) | EP1879549B1 (ja) |
JP (1) | JP4990268B2 (ja) |
KR (1) | KR100952109B1 (ja) |
CN (1) | CN101166512A (ja) |
AU (1) | AU2006239234A1 (ja) |
CA (1) | CA2604962C (ja) |
MX (1) | MX2007013571A (ja) |
WO (1) | WO2006116731A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012522043A (ja) * | 2009-03-31 | 2012-09-20 | ウェルスキン カンパニー,リミテッド | ジペプチドを有効成分として含む紫外線による紅斑反応抑制組成物 |
WO2022065433A1 (ja) * | 2020-09-28 | 2022-03-31 | 日産化学株式会社 | 毛髪用化粧料 |
Families Citing this family (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9616011B2 (en) | 2005-04-27 | 2017-04-11 | The Procter & Gamble Company | Personal care compositions |
US20080095732A1 (en) * | 2005-04-27 | 2008-04-24 | Rosemarie Osborne | Personal care compositions |
US20070020220A1 (en) | 2005-04-27 | 2007-01-25 | Procter & Gamble | Personal care compositions |
WO2007094999A2 (en) * | 2006-02-13 | 2007-08-23 | Stiefel Laboratories, Inc. | Ungual antifungal compositions |
US20070248550A1 (en) * | 2006-04-25 | 2007-10-25 | L'oreal | Cosmetic emulsions containing uncoated silicone elastomers and non silicone treated pigments |
US20080181956A1 (en) * | 2007-01-31 | 2008-07-31 | The Procter & Gamble Company | Oil-in-water personal care composition |
GB0704599D0 (en) * | 2007-03-09 | 2007-04-18 | Reckitt Benckiser Uk Ltd | Depilatory composition |
US20090028895A1 (en) * | 2007-07-27 | 2009-01-29 | Smith Walter P | Methods and compositions for reducing facial lines and wrinkles |
EP2183109B1 (en) | 2007-08-01 | 2019-07-03 | Avon Products, Inc. | Cosmetic applicator and method of making |
US8691248B2 (en) | 2008-03-11 | 2014-04-08 | Mary Kay Inc. | Stable three-phased emulsions |
US9005591B2 (en) * | 2008-05-16 | 2015-04-14 | Avon Products, Inc. | Compositions for imparting hydrophobicity and water repellency to hair |
CA2724392C (en) * | 2008-05-16 | 2017-02-14 | Avon Products, Inc. | Compositions for imparting superhydrophobicity |
US8318678B2 (en) * | 2008-05-30 | 2012-11-27 | Jan Marini Skin Research | Cosmetic compositions |
US8067037B2 (en) * | 2008-06-24 | 2011-11-29 | Marchese Frank P | Trehalose-containing topical drying composition and method of using same |
KR101393403B1 (ko) * | 2008-08-27 | 2014-05-14 | (주)아모레퍼시픽 | 콜라겐 펩티드를 함유하는 피부미용 개선용 조성물 |
US20100247693A1 (en) * | 2009-03-24 | 2010-09-30 | Marini Jan L | Cosmetic formulation to treat rosacea telangiectasia |
EP2415452B1 (en) * | 2009-03-31 | 2016-11-02 | Kao Corporation | Aqueous hair cleansing agent |
US20090263435A1 (en) * | 2009-05-07 | 2009-10-22 | L'oreal S.A. | Compositions and methods for minimizing and/or reducing the appearance of defects around eyes |
US8263052B1 (en) * | 2009-09-22 | 2012-09-11 | Marchese Frank P | Topical drying composition comprising encapsulated trehalose and method of using same |
EP2335677A1 (fr) * | 2009-12-17 | 2011-06-22 | L'Oréal | Composition cosmetique chargeante comprenant de l'alcool behenique a titre d'agent epaississant |
FR2954115B1 (fr) * | 2009-12-17 | 2012-05-11 | Oreal | Composition cosmetique comprenant de l'alcool behenique a titre d'agent epaississant, a stabilite de texture amelioree |
FR2954116B1 (fr) * | 2009-12-17 | 2012-05-11 | Oreal | Composition cosmetique chargeante comprenant de l'alcool behenique a titre d'agent epaississant |
US8337913B1 (en) * | 2010-10-07 | 2012-12-25 | Picazo Alejandra L | Cleaning swabs for fingernails |
US9113691B1 (en) | 2010-10-07 | 2015-08-25 | Alejandra L. Picazo | Cleaning swabs for fingernails |
CN103298449A (zh) * | 2010-11-19 | 2013-09-11 | 宝洁公司 | 用于抑制或降低胰蛋白酶活性的、基于环己-1,2,3,4,5,6-六醇和n-酰基氨基酸化合物的化妆品组合物和方法 |
JP2014524901A (ja) | 2011-06-13 | 2014-09-25 | ザ プロクター アンド ギャンブル カンパニー | ジアミドゲル化剤を含むパーソナルケア組成物及び使用方法 |
CN104039396A (zh) | 2011-06-13 | 2014-09-10 | 宝洁公司 | 包含pH可调的胶凝剂的个人护理组合物以及使用方法 |
EP2720666B1 (en) | 2011-06-20 | 2019-03-20 | The Procter and Gamble Company | Personal care compositions comprising shaped abrasive particles |
US20130011347A1 (en) | 2011-07-07 | 2013-01-10 | Paul Robert Tanner | Personal Care Compositions With Improved Solubility of a Solid Cosmetic Active |
US9192552B2 (en) | 2011-07-07 | 2015-11-24 | The Procter & Gamble Company | Personal care compositions with improved solubility of a solid UV active |
EP3248609B1 (en) | 2011-10-28 | 2019-10-16 | NeoStrata Company, Inc. | N-acyldipeptide derivatives and their uses |
US20130230474A1 (en) | 2012-03-01 | 2013-09-05 | The Procter & Gamble Company | Sunscreen Composition Comprising UV Composite |
US9549891B2 (en) | 2012-03-19 | 2017-01-24 | The Procter & Gamble Company | Superabsorbent polymers and sunscreen actives for use in skin care compositions |
US9271912B2 (en) | 2012-06-13 | 2016-03-01 | The Procter & Gamble Company | Personal care compositions comprising a pH tuneable gellant and methods of using |
US20140178314A1 (en) | 2012-12-19 | 2014-06-26 | The Procter & Gamble Company | Compositions and/or articles with improved solubility of a solid active |
EP2934474A4 (en) * | 2012-12-20 | 2016-10-12 | Elc Man Llc | MODULATION OF MELANOGENESIS BY TYROSINASE MODIFICATION BY PALMITOYLATION |
US9808654B2 (en) | 2013-02-11 | 2017-11-07 | Jan Marini Skin Research | Post procedure skin care gel and methods of use thereof |
JP6326601B2 (ja) * | 2013-03-13 | 2018-05-23 | アンティース ソシエテ アノニム | 皮膚更新のためのペプチド及び前記ペプチドを使用する方法 |
US9511144B2 (en) | 2013-03-14 | 2016-12-06 | The Proctor & Gamble Company | Cosmetic compositions and methods providing enhanced penetration of skin care actives |
US9005674B1 (en) | 2013-07-01 | 2015-04-14 | The Procter & Gamble Company | Method of improving the appearance of aging skin |
US20150080437A1 (en) | 2013-09-17 | 2015-03-19 | Corium International, Inc. | Topical adhesive composition, and device, for improving aesthetic appearance of skin |
JP5732165B1 (ja) * | 2014-05-14 | 2015-06-10 | 株式会社 資生堂 | うるおい補給用スティック状化粧料 |
JP2017530161A (ja) * | 2014-10-03 | 2017-10-12 | ザ プロクター アンド ギャンブルカンパニー | 油性成分の離散粒子を含む毛髪ケア組成物 |
JP6542364B2 (ja) | 2014-10-21 | 2019-07-10 | ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company | 皮膚の外観を改善する方法 |
US10406385B2 (en) | 2014-12-19 | 2019-09-10 | Northwestern University | Photoluminescent panthenol citrate biomaterials |
GB2549431A (en) | 2014-12-29 | 2017-10-18 | Kimberly Clark Co | Multifunctional base emulsion |
MX362727B (es) | 2014-12-29 | 2019-02-05 | Kimberly Clark Co | Emulsiones cosméticas. |
CA2988808C (en) | 2015-06-29 | 2021-05-25 | The Procter & Gamble Company | Superabsorbent polymers, waxes, oils, and starch powders for use in skincare compositions |
WO2017070078A1 (en) | 2015-10-22 | 2017-04-27 | The Procter & Gamble Company | Barrier patch of a foamed film and methods of improving skin appearance |
EP3364935B1 (en) | 2015-10-22 | 2019-11-20 | The Procter and Gamble Company | Barrier patch of a foamed film and methods of improving skin appearance |
US9872816B2 (en) | 2015-10-22 | 2018-01-23 | The Procter & Gamble Company | Barrier patch of a foamed film and methods of improving skin appearance |
CN109475483B (zh) * | 2016-03-24 | 2022-06-14 | 凯塞尔德国有限公司 | 用于皮肤护理和化妆品用途的天冬氨酰二肽 |
US11554108B2 (en) * | 2016-08-29 | 2023-01-17 | Xeropedix, Inc. | Methods and compositions for treating cutaneous fungal infections |
WO2018067847A1 (en) * | 2016-10-05 | 2018-04-12 | Baylor College Of Medicine | Structure of gii.4 norovirus protease -design of broad-spectrum protease inhibitors |
JP6974922B2 (ja) | 2017-01-09 | 2021-12-01 | ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company | 可溶性フィルムを有するバリアパッチ及び皮膚の外観を改善する方法 |
US10751265B2 (en) | 2017-01-09 | 2020-08-25 | The Procter & Gamble | Barrier patch with soluble film and methods of improving skin appearance |
US10857076B2 (en) | 2017-01-09 | 2020-12-08 | The Procter & Gamble Company | Barrier patch with soluble film and methods of improving skin appearance |
US11020334B2 (en) | 2017-02-17 | 2021-06-01 | Illustris Pharmaceuticals, Inc. | Compounds, compositions and use thereof |
EP3641952B1 (en) | 2017-06-22 | 2023-08-02 | The Procter & Gamble Company | Beauty care films including a water-soluble layer and a vapor-deposited coating |
CN111698984B (zh) | 2018-03-19 | 2023-11-14 | 宝洁公司 | 制备具有可溶性膜的阻隔贴片的方法 |
FR3082746A1 (fr) * | 2018-06-22 | 2019-12-27 | L'oreal | Emulsion comprenant un alkylpolyglycoside, des nacres et procede de maquillage et/ou de soin la mettant en œuvre |
WO2019243613A1 (en) * | 2018-06-22 | 2019-12-26 | L' Oreal | Emulsion comprising an alkylpolyglycoside and nacres, and makeup and/or care process using same |
CN113226278B (zh) | 2019-01-02 | 2023-07-21 | 宝洁公司 | 含有肽化合物和水前寺海苔胞外多糖提取物的皮肤护理组合物 |
CN111602822A (zh) * | 2019-02-25 | 2020-09-01 | 不二制油集团控股株式会社 | 用于抑制肝脂肪合成的食品组合物 |
EP4048409A1 (en) | 2019-10-24 | 2022-08-31 | The Procter & Gamble Company | Personal care composition preservatives level optimization |
EP4048408A1 (en) * | 2019-10-24 | 2022-08-31 | The Procter & Gamble Company | Personal care composition preservatives level optimization |
WO2021127318A1 (en) | 2019-12-19 | 2021-06-24 | The Procter & Gamble Company | Transparent composition with soluble scalp health active |
WO2022055974A1 (en) | 2020-09-08 | 2022-03-17 | Xylyx Bio, Inc. | Tissue-derived matrikine compositions and methods therefor |
WO2022092284A1 (ja) * | 2020-10-30 | 2022-05-05 | 日産化学株式会社 | 脂質ペプチドとショ糖エステルを含む組成物 |
WO2024028283A1 (en) * | 2022-08-03 | 2024-02-08 | Nanomol Technologies, S.L. | Vesicles based on glucose-derived surfactants and phytosterols |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07330572A (ja) * | 1994-06-14 | 1995-12-19 | Kao Corp | 皮膚柔軟化化粧料 |
JPH0912432A (ja) * | 1995-06-26 | 1997-01-14 | Kao Corp | 養毛・育毛料 |
JP2001500492A (ja) * | 1996-09-03 | 2001-01-16 | イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド | 抗炎症性ペプチドおよびその使用 |
JP2001522793A (ja) * | 1997-11-12 | 2001-11-20 | アルザ コーポレイション | 経皮電気輸送送達用の緩衝処理された薬物処方物 |
JP2004501166A (ja) * | 2000-06-16 | 2004-01-15 | ハーキュリーズ・インコーポレーテッド | 化学修飾ペプチド、組成物、並びに製造方法および使用 |
WO2005033255A1 (ja) * | 2003-10-03 | 2005-04-14 | Ajinomoto Co., Inc. | 洗浄剤組成物及びその製造方法 |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1985424A (en) * | 1933-03-23 | 1934-12-25 | Ici Ltd | Alkylene-oxide derivatives of polyhydroxyalkyl-alkylamides |
BE406221A (ja) * | 1933-11-15 | |||
US2438091A (en) * | 1943-09-06 | 1948-03-16 | American Cyanamid Co | Aspartic acid esters and their preparation |
BE498391A (ja) * | 1944-10-16 | |||
BE498392A (ja) * | 1945-11-09 | |||
US2528378A (en) * | 1947-09-20 | 1950-10-31 | John J Mccabe Jr | Metal salts of substituted quaternary hydroxy cycloimidinic acid metal alcoholates and process for preparation of same |
US2703798A (en) * | 1950-05-25 | 1955-03-08 | Commercial Solvents Corp | Detergents from nu-monoalkyl-glucamines |
US2658072A (en) * | 1951-05-17 | 1953-11-03 | Monsanto Chemicals | Process of preparing amine sulfonates and products obtained thereof |
US2694668A (en) * | 1952-03-10 | 1954-11-16 | Abbott Lab | Liquid multiple vitamin preparation and process of preparing the same |
US2826551A (en) * | 1954-01-04 | 1958-03-11 | Simoniz Co | Nontangling shampoo |
US2809971A (en) * | 1955-11-22 | 1957-10-15 | Olin Mathieson | Heavy-metal derivatives of 1-hydroxy-2-pyridinethiones and method of preparing same |
NL217218A (ja) | 1956-05-14 | |||
US3152046A (en) * | 1956-11-09 | 1964-10-06 | Kapral Ales Maria | Selenium disulfide dispersions |
GB849433A (en) | 1957-08-22 | 1960-09-28 | Raymond Woolston | Hair washing preparations |
US3155591A (en) * | 1961-12-06 | 1964-11-03 | Witco Chemical Corp | Hair rinse compostions of polyoxypropylene quaternary ammonium compounds |
US3236733A (en) * | 1963-09-05 | 1966-02-22 | Vanderbilt Co R T | Method of combatting dandruff with pyridinethiones metal salts detergent compositions |
US3332880A (en) * | 1965-01-04 | 1967-07-25 | Procter & Gamble | Detergent composition |
US3761418A (en) * | 1967-09-27 | 1973-09-25 | Procter & Gamble | Detergent compositions containing particle deposition enhancing agents |
US3755560A (en) * | 1971-06-30 | 1973-08-28 | Dow Chemical Co | Nongreasy cosmetic lotions |
US3753196A (en) * | 1971-10-05 | 1973-08-14 | Kulite Semiconductor Products | Transducers employing integral protective coatings and supports |
US3958581A (en) * | 1972-05-17 | 1976-05-25 | L'oreal | Cosmetic composition containing a cationic polymer and divalent metal salt for strengthening the hair |
CA1018893A (en) * | 1972-12-11 | 1977-10-11 | Roger C. Birkofer | Mild thickened shampoo compositions with conditioning properties |
US3964500A (en) * | 1973-12-26 | 1976-06-22 | Lever Brothers Company | Lusterizing shampoo containing a polysiloxane and a hair-bodying agent |
US4217914A (en) * | 1974-05-16 | 1980-08-19 | L'oreal | Quaternized polymer for use as a cosmetic agent in cosmetic compositions for the hair and skin |
US4422853A (en) * | 1974-05-16 | 1983-12-27 | L'oreal | Hair dyeing compositions containing quaternized polymer |
US3959461A (en) * | 1974-05-28 | 1976-05-25 | The United States Of America As Represented By The Secretary Of Agriculture | Hair cream rinse formulations containing quaternary ammonium salts |
US3929678A (en) * | 1974-08-01 | 1975-12-30 | Procter & Gamble | Detergent composition having enhanced particulate soil removal performance |
US4089945A (en) * | 1975-06-30 | 1978-05-16 | The Procter & Gamble Company | Antidandruff shampoos containing metallic cation complex to reduce in-use sulfide odor |
US4197865A (en) * | 1975-07-04 | 1980-04-15 | L'oreal | Treating hair with quaternized polymers |
AT365448B (de) * | 1975-07-04 | 1982-01-11 | Oreal | Kosmetische zubereitung |
US4152416A (en) * | 1976-09-17 | 1979-05-01 | Marra Dorothea C | Aerosol antiperspirant compositions delivering astringent salt with low mistiness and dustiness |
US4663158A (en) * | 1979-07-02 | 1987-05-05 | Clairol Incorporated | Hair conditioning composition containing cationic polymer and amphoteric surfactant and method for use |
US4507280A (en) * | 1979-07-02 | 1985-03-26 | Clairol Incorporated | Hair conditioning composition and method for use |
US4323683A (en) * | 1980-02-07 | 1982-04-06 | The Procter & Gamble Company | Process for making pyridinethione salts |
US4345080A (en) * | 1980-02-07 | 1982-08-17 | The Procter & Gamble Company | Pyridinethione salts and hair care compositions |
US4379753A (en) * | 1980-02-07 | 1983-04-12 | The Procter & Gamble Company | Hair care compositions |
US4387090A (en) * | 1980-12-22 | 1983-06-07 | The Procter & Gamble Company | Hair conditioning compositions |
US4529586A (en) * | 1980-07-11 | 1985-07-16 | Clairol Incorporated | Hair conditioning composition and process |
US4470982A (en) * | 1980-12-22 | 1984-09-11 | The Procter & Gamble Company | Shampoo compositions |
US4364837A (en) * | 1981-09-08 | 1982-12-21 | Lever Brothers Company | Shampoo compositions comprising saccharides |
US4421769A (en) * | 1981-09-29 | 1983-12-20 | The Procter & Gamble Company | Skin conditioning composition |
GB8401206D0 (en) * | 1984-01-17 | 1984-02-22 | Allied Colloids Ltd | Polymers and aqueous solutions |
GB8414950D0 (en) * | 1984-06-12 | 1984-07-18 | Allied Colloids Ltd | Cationic polyelectrolytes |
US4557853A (en) * | 1984-08-24 | 1985-12-10 | The Procter & Gamble Company | Skin cleansing compositions containing alkaline earth metal carbonates as skin feel agents |
CA1261276A (en) * | 1984-11-09 | 1989-09-26 | Mark B. Grote | Shampoo compositions |
USRE34584E (en) * | 1984-11-09 | 1994-04-12 | The Procter & Gamble Company | Shampoo compositions |
US5151210A (en) * | 1985-07-25 | 1992-09-29 | The Procter & Gamble Company | Shampoo compositions |
US4677120A (en) * | 1985-07-31 | 1987-06-30 | Molecular Design International | Topical prodrugs for treatment of acne and skin diseases |
GB8531118D0 (en) | 1985-12-18 | 1986-01-29 | Allied Colloids Ltd | Copolymers |
US4835148A (en) * | 1986-02-24 | 1989-05-30 | The Procter & Gamble Co. | Shampoo compositions comprising water-insoluble particulate anti-inflammatory agents |
GB8622797D0 (en) * | 1986-09-22 | 1986-10-29 | Allied Colloids Ltd | Polymeric particles |
EP0262945B1 (en) * | 1986-10-01 | 1994-01-05 | Ciba Specialty Chemicals Water Treatments Limited | Water soluble polymeric compositions |
US5143722B1 (en) * | 1986-12-19 | 1999-08-24 | Revlon Consumer Prod Corp | Cosmetic makeup compositions comprising water-in-oil emulsions containing pigment |
US4960764A (en) * | 1987-03-06 | 1990-10-02 | Richardson-Vicks Inc. | Oil-in-water-in-silicone emulsion compositions |
US4976953A (en) * | 1987-03-06 | 1990-12-11 | The Procter & Gamble Company | Skin conditioning/cleansing compositions containing propoxylated glycerol derivatives |
US4885107A (en) * | 1987-05-08 | 1989-12-05 | The Procter & Gamble Company | Shampoo compositions |
US4885311A (en) * | 1987-06-29 | 1989-12-05 | Molecular Design International | Topical transretinoids for treatment of acne and skin diseases |
USRE34075E (en) * | 1987-06-29 | 1992-09-22 | Molecular Design International, Inc. | Dermal uses of trans-retinoids for the treatment of cancer |
US5124356A (en) * | 1987-06-29 | 1992-06-23 | Molecular Design International, Inc. | Dermal uses of trans-retinoids for the treatment of photoaging |
US4800197A (en) * | 1987-07-17 | 1989-01-24 | Richardson-Vicks Inc. | Anti-acne composition |
EP0313305A3 (en) * | 1987-10-22 | 1990-02-07 | The Procter & Gamble Company | Photoprotection compositions comprising chelating agents |
US5151209A (en) * | 1987-11-19 | 1992-09-29 | The Procter & Gamble Company | Shampoo compositions |
EP0330369A1 (en) | 1988-02-16 | 1989-08-30 | Richardson-Vicks, Inc. | Skin conditioning composition |
US5049584A (en) * | 1988-12-14 | 1991-09-17 | Molecular Design International | Dermal uses of cis-retinoids for the treatment of cancer |
GB8909095D0 (en) * | 1989-04-21 | 1989-06-07 | Allied Colloids Ltd | Thickened aqueous compositions |
US5106609A (en) * | 1990-05-01 | 1992-04-21 | The Procter & Gamble Company | Vehicle systems for use in cosmetic compositions |
US5104646A (en) * | 1989-08-07 | 1992-04-14 | The Procter & Gamble Company | Vehicle systems for use in cosmetic compositions |
US5011681A (en) * | 1989-10-11 | 1991-04-30 | Richardson-Vicks, Inc. | Facial cleansing compositions |
US5120532A (en) * | 1990-04-06 | 1992-06-09 | The Procter & Gamble Company | Hair styling shampoos |
US5157020A (en) * | 1990-05-24 | 1992-10-20 | Research Corporation Tech., Inc. | Synthetic senescent cell antigen |
US5073371A (en) * | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
US5073372A (en) * | 1990-11-30 | 1991-12-17 | Richardson-Vicks, Inc. | Leave-on facial emulsion compositions |
DE69205466T2 (de) * | 1991-03-21 | 1996-05-30 | Procter & Gamble | Mittel zur Kontrolle von Hautfalten, die die Arg-Ser-Arg-Lys-Sequenzen enthalten. |
FR2691065B1 (fr) | 1992-05-18 | 1994-07-29 | Morelle Jean | Nouvelles compositions oculaires destinees a la prevention et au traitement de certains troubles de la vision. |
FR2699818B1 (fr) * | 1992-12-24 | 1995-02-03 | Oreal | Composition cosmétique ou pharmaceutique contenant en association un polyphénol et un extrait de gingko. |
GB2274585A (en) | 1993-01-23 | 1994-08-03 | Procter & Gamble | Make-up compositions for cosmetic use |
CN1100532C (zh) * | 1993-11-12 | 2003-02-05 | 普罗克特和甘保尔公司 | 含水杨酸和两性离子化合物的去皮屑组合物 |
US5681852A (en) * | 1993-11-12 | 1997-10-28 | The Procter & Gamble Company | Desquamation compositions |
US5922758A (en) * | 1994-09-21 | 1999-07-13 | The Procter & Gamble Company | Methods and compositions employing 2,4-dienoic acid esters of tocopherols to prevent or reduce skin damage |
JPH08217536A (ja) * | 1995-02-14 | 1996-08-27 | Tdk Corp | 正の抵抗温度係数を有する半導体磁器組成物及びその製造方法 |
US6060547A (en) | 1995-04-28 | 2000-05-09 | The Proctor & Gamble Company | Film forming foundation |
JP4547046B2 (ja) | 1995-06-29 | 2010-09-22 | ワイス・エルエルシー | ヒートセル |
US5607980A (en) * | 1995-07-24 | 1997-03-04 | The Procter & Gamble Company | Topical compositions having improved skin feel |
US5939082A (en) * | 1995-11-06 | 1999-08-17 | The Procter & Gamble Company | Methods of regulating skin appearance with vitamin B3 compound |
WO1997021423A1 (en) | 1995-12-11 | 1997-06-19 | The Procter & Gamble Company | Topical retinoid composition |
US5674478A (en) * | 1996-01-12 | 1997-10-07 | The Procter & Gamble Company | Hair conditioning compositions |
US5750122A (en) * | 1996-01-16 | 1998-05-12 | The Procter & Gamble Company | Compositions for treating hair or skin |
US5821250A (en) * | 1996-02-01 | 1998-10-13 | The Procter & Gamble Company | Dihydrobenzofuran and related compounds useful as anti-inflammatory agents |
DE19653736C2 (de) | 1996-12-12 | 2002-11-21 | Lancaster Group Gmbh | Kosmetisches Präparat mit Peptidzusatz |
US5997887A (en) * | 1997-11-10 | 1999-12-07 | The Procter & Gamble Company | Skin care compositions and method of improving skin appearance |
FR2783169B1 (fr) | 1998-09-15 | 2001-11-02 | Sederma Sa | Utilisation cosmetique ou dermopharmaceutique de peptides pour la cicatrisation et pour l'amelioration de l'aspect cutane lors du vieillissement naturel ou accelere (heliodermie, pollution) |
US6159485A (en) * | 1999-01-08 | 2000-12-12 | Yugenic Limited Partnership | N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use |
US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US6492326B1 (en) * | 1999-04-19 | 2002-12-10 | The Procter & Gamble Company | Skin care compositions containing combination of skin care actives |
US20020182237A1 (en) | 2001-03-22 | 2002-12-05 | The Procter & Gamble Company | Skin care compositions containing a sugar amine |
FR2827174B1 (fr) * | 2001-07-13 | 2004-08-06 | Soc Extraction Principes Actif | Utilisation de peptides pour augmenter l'adhesion cellulaire |
KR20040062602A (ko) * | 2001-10-30 | 2004-07-07 | 펜타팜아게 | 피부약학적 및 화장품학적 활성 올리고펩타이드 |
US7235249B2 (en) * | 2002-03-28 | 2007-06-26 | The Procter & Gamble Company | Methods for regulating the condition of mammalian keratinous tissue via topical application of vitamin B6 compositions |
JP3829186B2 (ja) | 2002-05-28 | 2006-10-04 | 独立行政法人産業技術総合研究所 | ポリペプチドがエネルギーにより切断される部位を予測する方法 |
FR2848116B1 (fr) * | 2002-12-10 | 2007-01-05 | Nuxe Lab | Composition cosmetique comprenant un inhibiteur des metallo-proteinases et un lipopeptide. |
US20040175347A1 (en) | 2003-03-04 | 2004-09-09 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using hexamidine compositions |
DE502004002556D1 (de) * | 2003-05-08 | 2007-02-15 | Pentapharm Ag | Tripeptide und deren derivate für die kosmetische verwendung zur verbesserung der hautstruktur |
ATE524486T1 (de) | 2005-04-27 | 2011-09-15 | Sederma S A S | Lys-thr-dipeptide und deren verwendung |
US20070020220A1 (en) | 2005-04-27 | 2007-01-25 | Procter & Gamble | Personal care compositions |
US20080095732A1 (en) * | 2005-04-27 | 2008-04-24 | Rosemarie Osborne | Personal care compositions |
-
2006
- 2006-04-26 US US11/411,285 patent/US20070020220A1/en not_active Abandoned
- 2006-04-27 CN CNA2006800142542A patent/CN101166512A/zh active Pending
- 2006-04-27 WO PCT/US2006/016418 patent/WO2006116731A2/en active Application Filing
- 2006-04-27 MX MX2007013571A patent/MX2007013571A/es active IP Right Grant
- 2006-04-27 AU AU2006239234A patent/AU2006239234A1/en not_active Abandoned
- 2006-04-27 EP EP06751883.7A patent/EP1879549B1/en active Active
- 2006-04-27 JP JP2008508009A patent/JP4990268B2/ja active Active
- 2006-04-27 KR KR1020077024186A patent/KR100952109B1/ko active IP Right Grant
- 2006-04-27 CA CA2604962A patent/CA2604962C/en active Active
-
2011
- 2011-04-07 US US13/082,285 patent/US8871717B2/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07330572A (ja) * | 1994-06-14 | 1995-12-19 | Kao Corp | 皮膚柔軟化化粧料 |
JPH0912432A (ja) * | 1995-06-26 | 1997-01-14 | Kao Corp | 養毛・育毛料 |
JP2001500492A (ja) * | 1996-09-03 | 2001-01-16 | イエダ・リサーチ・アンド・デベロツプメント・カンパニー・リミテツド | 抗炎症性ペプチドおよびその使用 |
JP2001522793A (ja) * | 1997-11-12 | 2001-11-20 | アルザ コーポレイション | 経皮電気輸送送達用の緩衝処理された薬物処方物 |
JP2004501166A (ja) * | 2000-06-16 | 2004-01-15 | ハーキュリーズ・インコーポレーテッド | 化学修飾ペプチド、組成物、並びに製造方法および使用 |
WO2005033255A1 (ja) * | 2003-10-03 | 2005-04-14 | Ajinomoto Co., Inc. | 洗浄剤組成物及びその製造方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012522043A (ja) * | 2009-03-31 | 2012-09-20 | ウェルスキン カンパニー,リミテッド | ジペプチドを有効成分として含む紫外線による紅斑反応抑制組成物 |
WO2022065433A1 (ja) * | 2020-09-28 | 2022-03-31 | 日産化学株式会社 | 毛髪用化粧料 |
Also Published As
Publication number | Publication date |
---|---|
US8871717B2 (en) | 2014-10-28 |
US20110183914A1 (en) | 2011-07-28 |
JP4990268B2 (ja) | 2012-08-01 |
WO2006116731A2 (en) | 2006-11-02 |
KR100952109B1 (ko) | 2010-04-13 |
US20070020220A1 (en) | 2007-01-25 |
CA2604962C (en) | 2012-02-28 |
MX2007013571A (es) | 2008-01-14 |
AU2006239234A1 (en) | 2006-11-02 |
KR20070116134A (ko) | 2007-12-06 |
EP1879549B1 (en) | 2018-09-12 |
WO2006116731A3 (en) | 2006-12-14 |
CA2604962A1 (en) | 2006-11-02 |
CN101166512A (zh) | 2008-04-23 |
EP1879549A2 (en) | 2008-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4990268B2 (ja) | ジペプチドを含むパーソナルケア組成物 | |
JP4256389B2 (ja) | テトラペプチドとトリペプチドの混合物を含む組成物 | |
JP2012516337A (ja) | スキンケア及び/又はヘアケア活性物質を使用した哺乳類ケラチン組織の調整 | |
US11285087B2 (en) | Cosmetic composition having increased skin contact and makeup persistence and method of manufacturing same | |
JP2008540580A (ja) | テトラヒドロクルクミンを含むパーソナルケア組成物を使用した哺乳類ケラチン組織の調整 | |
KR102006948B1 (ko) | 피부 미백용 화장료 조성물 | |
JP2013540766A (ja) | 化粧用スキンケア組成物 | |
JP2008540670A (ja) | 皮膚及び/又は毛髪手入れ活性物質を使用した哺乳類ケラチン組織の調整 | |
BRPI0814709B1 (pt) | Compostos, seus usos em aplicações cosméticas e cosmecêuticas e composições contendo os mesmos | |
KR102006952B1 (ko) | 주름 예방 및 개선용 화장료 조성물 | |
EP1971322A2 (en) | Personal care compositions comprising ppar. gamma. antagonists | |
WO2002011717A9 (en) | Cosmetics to support skin metabolism | |
WO2015147137A1 (ja) | セラミド配合外用剤組成物 | |
JP5455292B2 (ja) | 皮膚外用組成物 | |
JP6847948B2 (ja) | メラニン産生抑制剤、美白剤、線維芽細胞活性化剤、コラーゲン及び/又はエラスチン産生促進剤、及びシワ改善剤 | |
AU2014271339B2 (en) | Personal care compositions | |
JP2023552814A (ja) | スクロースエステル及び溶媒を含む化粧品組成物の製造方法 | |
US20220378679A1 (en) | Cosmetic product comprising a cosmetic composition contained in an applicator | |
JP2000247825A (ja) | 化粧料および外用剤 | |
AU2012203806A1 (en) | Personal care compositions | |
US20230285257A1 (en) | Cosmetic composition | |
JP2002308718A (ja) | 化粧品用組成物 | |
JP2001039815A (ja) | 化粧料および外用剤 | |
CN114081852A (zh) | 改善皮肤外观的组合物和方法 | |
JP2001158763A (ja) | 化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20100519 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100611 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100913 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100921 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101012 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101019 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101111 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101213 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110909 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111209 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111216 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120110 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120117 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120209 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120216 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120307 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120330 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120501 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4990268 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |